Intracranial hypertension is a condition where the pressure inside your skull rises above normal levels, putting stress on your brain and optic nerves. Normal intracranial pressure sits between 7 and 15 mmHg. When it climbs above 20 to 25 mmHg, it can cause headaches, vision problems, and in severe cases, permanent sight loss.
The condition comes in two forms: secondary intracranial hypertension, caused by an identifiable problem like a blood clot, tumor, or medication side effect, and idiopathic intracranial hypertension (IIH), where the pressure rises without an obvious structural cause. IIH was previously called pseudotumor cerebri because its symptoms mimic those of a brain tumor.
What Happens Inside the Skull
Your brain floats in cerebrospinal fluid (CSF), a clear liquid that cushions and protects it. This fluid circulates through chambers in the brain and around the spinal cord, constantly being produced and reabsorbed. When something disrupts this balance, either too much fluid is produced, too little is absorbed, or something else takes up space inside the skull, pressure builds.
The skull is a rigid container, so the brain has limited ways to compensate. CSF is the primary buffer: when pressure starts to rise, fluid shifts downward into the space around the spinal cord. Blood flow out of the brain can also adjust. But once these compensating mechanisms are overwhelmed, pressure climbs rapidly and symptoms appear.
Who Gets It
IIH disproportionately affects women of childbearing age. In adults, roughly 85% of cases occur in women, and more than 80% of adult patients are obese. The peak age of onset is around 25 years old. Incidence in the general population has been rising steadily, from about 0.5 to 2 per 100,000 people per year in 2002 to nearly 5 per 100,000 in 2016, a trend that tracks closely with rising obesity rates.
The link between body weight and intracranial hypertension is strong and dose-dependent. Compared to people at a normal weight, those who are moderately obese have about four times the odds of developing IIH, while those with extreme obesity face more than 15 times the risk. Higher BMI also correlates with more serious complications, including a greater chance of vision loss and recurrence after treatment.
Children can develop IIH too, though it’s less common. In younger children (under 12), the condition looks different: there’s no strong female predominance and obesity plays a smaller role. In adolescents, the pattern shifts to resemble the adult form, with girls and those with higher body weight affected far more often.
Symptoms to Recognize
Headache is the hallmark symptom. It’s often described as a pressure-type pain that worsens with straining, coughing, or lying down. For many people it’s daily or near-daily and can be severe enough to interfere with work and sleep.
Vision problems are the most concerning symptom because they can become permanent. These include brief episodes where vision goes grey or black for a few seconds (called transient visual obscurations), blurry vision, double vision, and in advanced cases, progressive loss of peripheral vision or overall visual sharpness. Up to 87% of patients experience some degree of visual disturbance, ranging from mild blind spot enlargement to more significant field loss.
Pulsatile tinnitus, a rhythmic whooshing or heartbeat-like sound in one or both ears, is another common symptom. It happens because elevated pressure affects blood flow through the venous channels near the ear. Some patients have structural variations in the walls of these channels that make turbulent blood flow more audible, which may explain why tinnitus is more prominent in some people than others.
Secondary Causes
When intracranial hypertension has a clear underlying trigger, it’s classified as secondary. Blood clots in the brain’s venous drainage system (cerebral venous sinus thrombosis) are one of the more serious causes. Infections like meningitis, brain tumors, and head injuries can all raise intracranial pressure as well.
Several medications are known to trigger the condition. The strongest associations are with vitamin A derivatives (including high-dose supplements and acne medications), tetracycline-class antibiotics, growth hormone therapy, and lithium. Corticosteroids, particularly during withdrawal, carry a moderate risk. A longer list of drugs with weaker associations includes certain hormonal contraceptives, some fluoroquinolone antibiotics, and the seizure medication valproic acid. If symptoms appear after starting a new medication, that timing is an important clue.
How It’s Diagnosed
Diagnosis follows a set of criteria that essentially require ruling out other explanations. Your doctor will look for signs of elevated pressure (most importantly, swelling of the optic nerves visible during an eye exam), confirm that brain imaging shows no tumor, blocked fluid chambers, or other structural problem, and verify that you’re neurologically normal aside from the pressure-related symptoms.
A lumbar puncture (spinal tap) provides the definitive measurement. During this procedure, a needle is inserted into the lower spine and the “opening pressure” of the CSF is recorded. The normal range is 10 to 25 cm of water. Pressures above 25 cm support a diagnosis of intracranial hypertension, though body weight can influence the reading, and some otherwise healthy people naturally run slightly higher. Diagnosis is most confident when the pressure is clearly elevated and other findings line up.
Brain imaging, typically an MRI, is a required step. While the scan shouldn’t show a mass or blocked fluid pathways, certain subtle findings actually support the diagnosis: a partially empty pocket where the pituitary gland sits (empty sella), distended fluid sleeves around the optic nerves, or narrowing of the brain’s venous drainage channels.
Treatment Options
Weight loss is considered the most effective long-term intervention for IIH patients who are overweight. Losing even 5 to 10% of body weight can significantly reduce intracranial pressure and improve symptoms. For many patients, sustained weight management is what keeps the condition from coming back.
The primary medication used to lower CSF production is acetazolamide, a drug that reduces fluid output by acting on an enzyme in the brain’s fluid-producing tissue. Adults typically start at 1,000 mg per day and may gradually increase up to 2 to 4 grams daily, depending on response and tolerance. About 40% of patients in a major clinical trial tolerated the highest doses without significant impact on daily life, though many find doses above 2 grams per day difficult to stick with. Common side effects include tingling in the fingers and toes, altered taste (especially with carbonated drinks), fatigue, and digestive upset.
Surgical Options
Surgery becomes necessary when medications fail or when vision is deteriorating rapidly. The two traditional approaches target different primary symptoms.
Optic nerve sheath fenestration is preferred when vision loss is the main concern. The procedure creates small slits in the membrane surrounding the optic nerve, allowing trapped fluid to drain and relieving pressure on the nerve. In one of the largest case series, 94% of eyes showed improved visual sharpness and 88% had stabilized or improved visual fields afterward. It’s less effective for headaches, with only about a third of headache-dominant patients reporting improvement.
CSF shunting redirects excess fluid from the brain or spine to another body cavity (usually the abdomen) through a thin tube placed under the skin. Shunts are generally chosen when headache is the dominant problem, with or without vision issues. About 80 to 89% of patients see significant improvement in their symptoms. The trade-off is a relatively high rate of complications and revisions: roughly 20% of shunt patients experience complications, and 35% eventually need a revision surgery because the shunt clogs, disconnects, or stops working properly.
Venous sinus stenting is a newer, less invasive option for patients whose elevated pressure is linked to narrowing of the brain’s venous drainage channels. A small expandable tube is placed inside the narrowed vein to hold it open, improving drainage. Outcomes have been encouraging: pulsatile tinnitus resolves in about 90% of cases, visual problems improve in nearly 89%, and headaches resolve in about 79%. Complete neurological recovery occurs in roughly 86% of patients. The most common complications include clot formation inside the stent and, rarely, bleeding. Mortality is low at about 0.7%, but the procedure requires lifelong blood-thinning medication afterward.
Vision Loss and Long-Term Outlook
The biggest concern with intracranial hypertension is irreversible damage to the optic nerves. The swelling caused by elevated pressure (papilledema) can, over time, destroy nerve fibers. Some degree of visual deficit, whether it’s an enlarged blind spot, narrowed peripheral vision, or reduced sharpness, occurs in up to 87% of patients at some point during the course of the disease. Most of this is mild and reversible with treatment.
Severe, permanent blindness is uncommon but real. Studies estimate that 1 to 2% of newly diagnosed IIH patients become legally blind in a given year. The risk is highest in patients who delay treatment, have rapidly progressive papilledema, or have difficulty controlling their weight. Regular monitoring with visual field testing is essential, because vision loss from papilledema often creeps in from the periphery and patients may not notice it until it’s advanced.
With appropriate treatment, most people with intracranial hypertension can manage the condition effectively. The biggest predictors of a good outcome are early diagnosis, consistent follow-up eye exams, and for those who are overweight, sustained weight reduction.